Author of

• 16879

  +

  P1.07 - Poster Session with Presenters Present (ID 459)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: SCLC/Neuroendocrine Tumors
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 16927

    +

    P1.07-048 - Clinical Impact of the Relationship between Post-Progression Survival and Overall Survival in Extensive Disease Small Cell Lung Cancer Patients (ID 4303)

    14:30 - 14:30  |  Author(s): M. Yamada
    • Abstract

    Background:
    The effects of first-line chemotherapy on overall survival (OS) might be confounded by subsequent therapies in patients with small-cell lung cancer (SCLC). Therefore, by using individual-level data, we aimed to determine the relationships between progression-free survival (PFS) or post-progression survival (PPS) and OS after first-line chemotherapies in patients with extensive disease SCLC (ED-SCLC) treated with carboplatin plus etoposide.
    
    Methods:
    Between July 1998 and December 2014, we analyzed 63 cases of patients with ED-SCLC who were treated with carboplatin and etoposide as first-line chemotherapy. The relationships of PFS and PPS with OS were analyzed at the individual level.
    
    Results:
    Spearman rank correlation analysis and linear regression analysis showed that PPS was strongly correlated with OS (r = 0.90, p < 0.05, R[2 ]= 0.71) and PFS was moderately correlated with OS (r = 0.72, p < 0.05, R[2] = 0.62). Type of relapse (refractory/sensitive) and the number of regimens administered after disease progression after the first-line chemotherapy were both significantly associated with PPS (p < 0.05).
    
    Conclusion:
    PPS has a stronger relationship with OS than does PFS in ED-SCLC patients who have received first-line chemotherapy. In addition, type of relapse (refractory/sensitive) after first-line treatment and the number of additional regimens after first-line treatment are significant independent prognostic factors for PPS. These results suggest that treatments administered after first-line chemotherapy affect the OS of ED-SCLC patients treated with carboplatin plus etoposide.